In addition, some aspects of GLP-1 beyond weight loss, such as preclinical evidence on GLP-1 effects in directly modulating the hypothalamuspituitarygonadal axis, or the effects of GLP-1RA on clinical and biochemical expression of hyperandrogenism, still deserve a greater insight, especially in light of a possible therapeutic use in PCOS women independently of obesity
In light of this information, NCL offers this advice to consumers when considering GLP-1 treatment options: Before seeking treatment with a GLP-1 drug, talk to your doctor or health provider to determine if you are a candidate for treatment based on your risk factors and degree of obesity
If you have PCOS: You might need a bit more patience
Or, if they stay on them long term without improving food quality, will their bodies be forced to struggle through nutrient deficiency and develop new diseases
Retatrutide is not officially classified as GLP-3 or GLP-R. However, researchers, buyers, and industry observers sometimes use terms such as GLP-3 , GLP3 peptide , GLP-R , triple agonist peptide , or next-generation GLP-1 when discussing compounds that extend beyond traditional GLP-1 research models
Semaglutide works on one receptor (GLP-1) while tirzepatide works on two receptors (GLP-1 and GIP)